KWKelcie D. Willis

Kelcie D. Willis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kelcie D. Willis has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Addressing death anxiety in caregivers of patients with malignant glioma: A Phase 1a Define trial investigating the suitability of CALM therapy

    by Kelcie D. Willis, Lillia Thumma, Amber Fox, Morgan P. Reid, Bruce Rybarczyk, Suzanne E. Mazzeo, Jared W. Keeley, Gary Rodin, Ashlee R. Loughan

    Objectives: Managing Cancer and Living Meaningfully (CALM) therapy may be a beneficial intervention for addressing death anxiety in caregivers yet has not been formally evaluated in this population. The purpose of this Phase 1a Define trial was to evaluate the suitability of CALM for caregivers of patients diagnosed with malignant glioma using qualitative stakeholder interviews prior to pilot testing. Methods: Twenty-two bereaved caregivers participated in a focus group and completed subsequent caregiver-reported outcome measures. During the focus group, caregivers received information about CALM and provided feedback on the intervention’s relevance and recommendations to improve its content and delivery for the caregiving experience. A team of coders qualitatively analyzed responses using thematic, deductive, latent analysis (kappa = 0.86). Results: Results suggest that CALM is highly relevant to the caregiving experience and may benefit caregivers emotionally, increase preparedness and self-efficacy in their role, improve their communication with the patient, and provide a unique opportunity to receive specialized care. Potential hurdles for participation included limited time and energy, concerns about burdening the patient by sharing their emotions, and worries that their loved one would not be emotionally or cognitively capable of participating. Participants also recommended additional content areas relevant to caregiving (i.e., burden and bereavement) and provided suggestions to improve CALM’s delivery (timing, initial presentation, session format, and logistics). Significance of results: Participants’ feedback was largely positive and supports piloting an optimized CALM protocol among malignant glioma caregivers. Further research is needed to determine CALM’s effectiveness in caregivers of patients with malignant gliomas.

  • Burdened and Burned Out: Health Behavior Disruptions in Neuro-Oncology Caregivers

    by Kelcie D. Willis, Margaret M. Byrne, Deanna Witte, Kristen J. Wells, Alissa A. Thomas, Maija Reblin

    Background: Caregivers of patients with primary brain tumors (PBTs) experience psychological distress and often neglect their own health. This study examined how caregivers perceive changes in their health behaviors (e.g., sleep, diet, exercise, and substance use) and the associated risk factors for these changes. Methods: We utilized baseline survey data from a randomized controlled trial of 116 caregivers of patients with PBTs. Results: Caregivers most frequently reported impacts to their sleep (71%), exercise (58%), and meals prepared at home (56%). Caregiving burden was consistently associated with perceived changes in multiple health behaviors, even after controlling for depression and anxiety. Younger caregivers and those identifying as racial/ethnic minorities were more likely to report changes in health behaviors. Conclusions: Findings highlight burden as a central risk factor for declines in self-care and suggest that interventions that promote both emotional and physical well-being in this vulnerable population are warranted.

  • Improved coping and self-efficacy drive improvements in mood among caregivers of patients with primary malignant brain tumors: Results from a randomized controlled trial

    by Kelcie D Willis, Deborah A Forst, Nora Horick, Sumita M Strander, Jessica Whitman, Amy Corveleyn, Timothy Sannes, Jennifer S Temel, Joseph A Greer, Areej El-Jawahri, et al.

    Background: In a recent randomized controlled trial, caregivers of patients diagnosed with primary malignant brain tumors (PMBT) who received NeuroCARE—a 6-session, cognitive-behavioral, telehealth intervention—demonstrated improved anxiety and depression symptoms at 11 weeks post-randomization compared to caregivers assigned to usual care (UC). We explored whether these intervention effects were mediated by improvements in coping and self-efficacy. Methods: We examined data from caregivers of patients with PMBT randomized to receive either NeuroCARE or UC (N = 120). Participants completed assessments of anxiety and depression symptoms (Hospital Anxiety and Depression Scale), coping (Measure of Current Status), and self-efficacy (Lewis Cancer Self-Efficacy Scale) at baseline, 11 weeks, and 16 weeks. We conducted 4 simple mediation regression models using the Preacher & Hayes bootstrapping method to examine whether improvements in coping or self-efficacy from baseline to 11 weeks mediated intervention effects on 11-week anxiety or depression symptoms. Results: The sample (N = 120; Mage = 53 years) predominantly consisted of participants who self-identified as female (82.5%), White (91.7%), and spouses/partners (70.0%) caring for a patient with glioblastoma (84%). Improvements in 11-week anxiety symptoms in caregivers assigned to NeuroCARE were mediated by improved coping (indirect effect = −1.44, SE = 0.49, 95% CI [−2.50, −0.54]) and self-efficacy (indirect effect=−1.29, SE = 0.42, 95% CI [−2.16, −0.52]). Similarly, improvements in 11-week depression symptoms were mediated by improved coping (indirect effect=-1.43, SE = 0.38, 95% CI [−2.21, −0.74]) and self-efficacy (indirect effect = −0.95, SE = 0.32, 95% CI [−1.60, −0.36]). Conclusion: The NeuroCARE intervention improves mood by enhancing coping skills and improving caregivers’ self-efficacy in caregivers of patients with PMBT.

  • NeuroCARE: A Randomized Controlled Trial of a Psychological Intervention for Caregivers of Patients With Primary Malignant Brain Tumors

    by Deborah A. Forst, Alyx F. Podgurski, Sumita M. Strander, Jessica D. Whitman, Shibani Datta, Kedie Pintro, Nora K. Horick, Kelcie D. Willis, Timothy S. Sannes, Joseph A. Greer, et al.

    PURPOSE: Caregivers of patients with primary malignant brain tumors (PMBT) experience significant psychological distress. We assessed the effect of a psychological intervention (NeuroCARE) on anxiety symptoms among PMBT caregivers. METHODS: We conducted a randomized trial of NeuroCARE versus usual care in PMBT caregivers with elevated anxiety (Generalized Anxiety Disorder-7 score ≥5) within 6 months of the patient's diagnosis. NeuroCARE was developed for PMBT caregivers and consists of six telehealth sessions with a behavioral health specialist. Participants completed surveys at baseline, 11-week (postintervention), and 16-week (1-month postintervention) time points. The primary outcome was 11-week anxiety symptoms (Hospital Anxiety and Depression Scale [HADS]-Anxiety Subscale). We also measured depression symptoms (HADS-Depression Subscale), quality of life (QOL; Caregiver QOL survey), caregiver burden (Caregiver Reaction Assessment), self-efficacy (Lewis Cancer Self-Efficacy Scale), coping (Measure of Current Status), and post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist for DSM-5). We conducted analysis of covariance and linear mixed-effects regression analyses to examine intervention effects on study outcomes. RESULTS: We enrolled 120 caregivers (60/group) between October 2019 and June 2022; 105 were evaluable for the primary outcome. At 11 weeks, NeuroCARE participants reported significantly lower anxiety symptoms than usual care participants ( M , 8.87 v 10.69; P = .008). NeuroCARE caregivers also reported significantly lower depression symptoms ( M , 6.08 v 7.77; P = .004), and better self-efficacy ( M , 128.81 v 111.17; P < .001) and coping ( M , 32.25 v 25.65; P < .001) at 11 weeks. Study groups did not differ significantly in 11-week QOL, caregiver burden, or PTSD symptoms. In longitudinal analyses, intervention effects on depression symptoms, self-efficacy, and coping were sustained. CONCLUSION: A novel, population-specific psychological intervention led to improved anxiety and depression symptoms, self-efficacy, and coping among PMBT caregivers.


  • Effects of Adjuvant Endocrine Therapy–Specific Perceptions on Response to a Behavioral Intervention for Adjuvant Endocrine Therapy Adherence in Patients With Breast Cancer

    by Kelcie D. Willis, Emily A. Walsh, Laura E. Dunderdale, Kathryn Post, Nora Horick, Michael H. Antoni, Steven A. Safren, Ann H. Partridge, Jeffrey Peppercorn, Elyse R. Park, et al.

    PURPOSE: Adjuvant endocrine therapy (AET) is a life-saving medication for patients with hormone-sensitive breast cancer, yet many struggle with adherence, warranting behavioral intervention. In our recent trial, participation in a group cognitive behavioral intervention (STRIDE) for symptom management and adherence was associated with improvements in symptom distress, coping, quality of life, and mood. We now explore whether baseline patient- and medication-specific factors—which may be modifiable by clinician-led discussions—moderated the effect of STRIDE on adherence rates. METHODS: From October 2019 to June 2021, 100 patients with early-stage breast cancer reporting AET-related distress were enrolled and randomly assigned to STRIDE or a medication monitoring (MM) control group. All patients stored their AET in electronic pill bottles to track objective adherence. Patients also self-reported their adherence on the Medication Adherence Report Scale-5 and their perceptions of AET on the Cancer Therapy Satisfaction Questionnaire at baseline. We conducted hierarchical linear modeling to test moderators of intervention effects on objective adherence rates. We report the time × group × moderator effects. RESULTS: Among patients reporting greater perceived difficulties with AET adherence at baseline, STRIDE participants had higher adherence rates over time compared with MM ( b = –13.80; SE = 4.56; P < .01). Patients with greater expectations of therapeutic benefit from AET also had improved adherence rates if they were assigned to STRIDE, versus MM ( b = 0.25; SE = 0.10; P = .01). Patients who perceived taking AET as convenient and had been taking their AET for less time had higher adherence rates in STRIDE, versus MM. CONCLUSION: The current study identified patient- and medication-specific factors that may augment AET adherence interventions and may be modifiable through clinician-led discussions, such as perceptions of adherence problems, therapeutic efficacy, and convenience of AET.


  • Primary brain tumor representation in the post-traumatic growth literature: A scoping review

    by Julia K Brechbiel, Kelcie D Willis, Morgan P Reid, Autumn Lanoye, Farah J Aslanzadeh, Amber M Fox, Sarah Ellen Braun, Ashlee R Loughan

    Post-traumatic growth (PTG) has been extensively explored within general oncology, yet little is known about the experience of PTG in neuro-oncology. This study aimed to determine the representation of patients with primary brain tumors (PBT) in the PTG literature. PsycINFO, PubMed, and CINAHL were systematically searched from inception to December 2022. Search terms were related to personal growth and positive reactions to cancer. Articles were first screened by titles and abstracts, then full texts were reviewed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses method. A total of 382 articles met the inclusion criteria. Of those, 13 included patients with PBT. Over 100 000 cancer patients were represented, with 0.79% having a PBT. Most research focused on low-grade gliomas. PTG negatively correlated with post-traumatic stress symptoms and avoidant coping. In the sole longitudinal study, patients with PBT demonstrated improved PTG after 1 year. Three quasi-experimental studies investigated the effect of mindfulness-based interventions with mixed-cancer samples and demonstrated improvement in PTG. The inclusion rate of patients with PBT in the PTG literature was significantly lower than the population prevalence rate (1.3% of cancer diagnoses). Relatively few studies focused exclusively on how patients with PBT experience PTG (k = 5), and those that did only included low-grade glioma. The experience of PTG in those with high-grade glioma remains unknown. Patients with PBT are scarcely included in research on PTG interventions. Few studies examined the relationship between PTG and medical, cognitive, or psychological characteristics. Our understanding of the PTG experience in neuro-oncology remains extremely limited.


  • Closing the Caregiving Gap: Considerations for Pancreatic and Periampullary Cancer Caregivers

    by Kelcie D. Willis, Jamie M. Jacobs

    Family caregivers of patients with pancreatic cancer face immense practical challenges and high emotional burden; they lack tailored support. Investigators advocate for more research, supportive interventions, and policy changes.


  • Open Access

    CTNI-06. IMPROVING INSOMNIA IN PATIENTS WITH PRIMARY BRAIN TUMORS USING COGNITIVE BEHAVIORAL THERAPY: RESULTS FROM AN NRG NCORP PILOT TRIAL

    by Ashlee Loughan, Autumn Lanoye, Kelcie Willis, Amber Fox, Alicia Zukas, Scott Ravyts

    Sleep disturbance is among the most common symptoms endorsed by patients with primary brain tumor (PwPBT), with many reporting clinically-elevated insomnia and poor management of sleep-related symptoms by their medical team. Though Cognitive Behavioral Therapy for Insomnia (CBT-I) remains the front-line treatment for sleep disturbance, CBT-I has yet to be evaluated in PwPBT. PwPBT were recruited locally by direct referral and fliers, and nationally by social media support group postings. Forty PwPBT and insomnia enrolled in a six-week group-based telehealth CBT-I phase IIa single-arm proof-of-concept trial: 50.0% female, 68.2% non-Hispanic white, 55.0% high-grade, 42.5% oligodendroglioma, Mage = 52.4 (SD = 12.0, range 31-77). Participants completed data collection at baseline and post-intervention. Self-report measures assessed insomnia (ISI), fatigue (BFI), mood (PHQ-9, GAD-7) and quality-of-life (QLQ-30). Cognitive assessment included measures of attention (WAIS-IV Digits, TMT), verbal fluency (COWAT) and memory (HVLT). Intervention effects for self-report outcomes were analyzed using paired t-tests; effects for cognitive outcomes were analyzed using repeated-measures ANCOVA controlling for age. Among those with complete data (n=34), significant improvements were identified for insomnia (t(33) = 8.6, p < .001, Cohen’s d = 1.5) and fatigue (t(30) = 4.7, p < .001, Cohen’s d = 0.8) symptoms. Depression (t(33) = 5.2, p < .001, Cohen’s d = 0.9) and anxiety symptoms (t(33) = 4.2, p < .001, Cohen’s d = 0.7) also improved. Quality-of-life improved with respect to role (t(33) = 2.8, p = .01, Cohen’s d = 0.5), emotional (t(33) = 2.8, p = .01, Cohen’s d = 0.5), cognitive (t(33) = 3.9, p < .001, Cohen’s d = 0.7), and social functioning (t(33) = 3.5, p = .001, Cohen’s d = 0.6)—but not physical functioning (t(33) = 0.5, p = .60, Cohen’s d = 0.1). No clinically or statistically significant cognitive changes were found. This trial is the first to preliminarily assess efficacy of CBT-I, a non-pharmacological treatment for insomnia, in PwPBT. Results suggest promising benefit of CBT-I in insomnia severity, fatigue, mood, and most quality-of-life indices for individuals challenged by PBT and insomnia. These findings support further study in a scientifically rigorous phase IIb randomized feasibility trial.

  • Open Access

    Measuring and understanding death anxiety in caregivers of patients with primary brain tumor

    by Kelcie Willis, Scott G. Ravyts, Autumn Lanoye, Morgan P. Reid, Farah J. Aslanzadeh, Sarah Ellen Braun, Dace Svikis, Gary Rodin, Ashlee R. Loughan

    Objective: Caregivers of patients with primary brain tumor (PBT) describe feeling preoccupied with the inevitability of their loved one's death. However, there are currently no validated instruments to assess death anxiety in caregivers. This study sought to examine (1) the psychometric properties of the Death and Dying Distress Scale (DADDS), adapted for caregivers (DADDS-CG), and (2) the prevalence and correlates of death anxiety in caregivers of patients with PBT.Methods: Caregivers (N = 67) of patients with PBT completed the DADDS-CG, Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder (GAD-7), Fear of Cancer Recurrence (FCR-7), and God Locus of Health Control (GLHC). Caregivers’ sociodemographic information and patients’ medical characteristics were also collected. Preliminary examination of the psychometric properties of the DADDS-CG was conducted using exploratory factor analysis, Cronbach's alpha, and correlations. The prevalence and risk factors of death anxiety were assessed using frequencies, pair-wise comparisons, and correlations.Results: Factor analysis of the DADDS-CG revealed a two-factor structure consistent with the original DADDS. The DADDS-CG demonstrated excellent internal consistency, convergent validity with the PHQ-9, GAD-7, and FCR-7, and discriminant validity with the GLHC. Over two-thirds of caregivers reported moderate-to-severe symptoms of death anxiety. Death anxiety was highest in women and caregivers of patients with high-grade PBT.Significance of results: The DADDS-CG demonstrates sound psychometric properties in caregivers of patients with PBT, who report high levels of death anxiety. Further research is needed to support the measure's value in clinical care and research — both in this population and other caregivers — in order to address this unmet, psychosocial need.


  • Open Access

    Same storm, different boat: The global impact of COVID‐19 on palliative care

    by Kelcie D. Willis, Seema Rajesh Rao, Michelle Normen, Janet de Groot, Lynn Calman, Ozan Bahcivan, Isabel Centeno, Dwain C. Fehon

    Objective: The COVID-19 pandemic has had a complex and profound impact on the provision of palliative care globally. To support learning from palliative care providers and researchers worldwide, the Education Subcommittee of International Psycho-Oncology Society (IPOS) Palliative Care Special Interest Group developed a webinar with presentations by and discussion with eight international palliative care leaders. Methods: Presentations were content rich; the speakers used both quantitative (e.g., sharing recent statistical findings) and qualitative (e.g., narrative storytelling, anecdotal experiences) approaches to portray the effect of COVID-19 in their region. Subsequent to the webinar, the committee collectively identified five themes conveyed by the presenters through consensus. Results: The themes included: (1) altered accessibility to palliative care, with socio-economic status impacting virtual health availability; (2) reduced opportunities to preserve dignity, as survival has been prioritized over preserving the humanity of patients and their loved ones; (3) complicated grief and bereavement arising from social distancing requirements; (4) greater awareness of the importance of sustaining health provider well-being; and (5) the development of valuable innovations across nations, institutions, disciplines, and communities. Conclusions: Overall, the webinar facilitated valuable connection for global learning and identified opportunities for research and clinical interventions. In an ongoing crisis that has exacerbated isolation, we will need to continue to learn and lean on one another as a global community to navigate ongoing challenges of the COVID-19 pandemic.